FIGURE 5.

Survival of adult T‐cell leukemia/lymphoma (ATLL) patients according to treatment modalities, stratified by CD28 protein expression. A, Overall survival (OS) of the ATLL patients who did not receive allogeneic hematopoietic stem cell transplantation (HSCT) (n = 92). B, OS of the 42 patients with CD28 overexpression and the 50 with non‐overexpression. C, Among the nontransplanted ATLL patients with an aggressive variant, OS of the 38 patients with CD28 overexpression and the 44 with non‐overexpression. D, Among the nontransplanted ATLL patients with an indolent variant, OS of the four patients with CD28 overexpression and the six with non‐overexpression. E, Among the ATLL patients who received allogeneic HSCT, survival from the day of HSCT in the 13 patients with CD28 overexpression and the 15 with non‐overexpression. F, Among the ATLL patients who received mogamulizumab‐containing treatment, but not allogeneic HSCT, survival from the day of the first dose of mogamulizumab in the 22 patients with CD28 overexpression and the 25 with non‐overexpression. G, For patients who received mogamulizumab‐containing treatment but not allogeneic HSCT and who had CCR4 mutations, survival from the day of the first dose of mogamulizumab in the seven patients with CD28 overexpression and the five with non‐overexpression is shown. H, For patients who received mogamulizumab‐containing treatment but not allogeneic HSCT and who lacked CCR4 mutations, survival from the day of the first dose of mogamulizumab in the 15 patients with CD28 overexpression and the 20 with non‐overexpression is shown. Survival curves were compared using the log‐rank test, and the P‐value is indicated in each panel. No., number